European Pharmaceutical Review

AUGUST 21, 2023

Its diabetes treatment Mounjaro led this outcome. Part of this growth was driven by Arexvy, which in May 2023, became the world’s first approved RSV vaccine for older adults. billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted.

Biosimilars 98

Biosimilars Diabetes Vaccines 98

pharmaphorum

SEPTEMBER 30, 2022

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. 8,414,921), which covers the co-formulation of sitagliptin and metformin and is due to expire in 2029.

Diabetes 59

Diabetes Vaccines 59

Pharmaceutical Technology

MAY 16, 2023

increase in market capitalisation over Q1 2023, fuelled by its robust portfolio of diabetes and obesity treatments – in particular, its line of glucagon-like peptide 1 receptor agonist (GLP-1) Type 2 diabetes drugs Ozempic, Rybelsus and Victoza. million by 2029. Novo Nordisk reported an 18.2%

Diabetes 52

Diabetes Vaccines Drug Pricing 52